Physiologically Balanced Fosnetupitant Injectables for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Fosnetupitant formulations face challenges with degradation, solubility issues, and bioavailability problems, requiring improved stability, solubility, and physiological tolerance for effective injection doses and formulations.
Innovation Solution
The development of lyophilized and liquid injectable formulations of fosnetupitant with balanced ratios of fosnetupitant and netupitant, controlled pH, and specific excipients like sodium hydroxide and disodium edetate to maintain stability and solubility, avoiding unwanted conversion to netupitant and reducing injection site reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If fosnetupitant is formulated as a liquid solution or lyophilized powder with controlled pH and specific excipients, then stability and solubility are improved, but formulation complexity increases
Solution Approach 1:
The patent applies parameter changes by controlling pH within specific ranges (7.0-9.0 for liquid formulations, 7.5-8.5 for lyophilized formulations) and adjusting temperature conditions during storage. These parameter optimizations improve formulation stability while managing the inherent complexity through systematic control rather than arbitrary formulation choices
Solution Approach 2:
The patent introduces specific excipients as intermediaries: disodium edetate (0.01-1.0 mg/mL) acts as a stabilizing agent, mannitol (10-100 mg/mL) serves as a protective excipient for lyophilized formulations, and sodium hydroxide or hydrochloric acid are used as pH adjusting agents. These intermediary substances mediate between the active ingredient and the formulation environment, improving stability without requiring complex formulation designs
2Quantity of substance
If fosnetupitant concentration is increased to achieve therapeutic efficacy, then treatment effectiveness improves, but solubility issues and degradation increase
Solution Approach 1:
The patent optimizes pH parameters to specific ranges (7.0-9.0 for liquid, 7.5-8.5 for lyophilized) that maximize fosnetupitant solubility and minimize degradation. Temperature parameters are also controlled during storage and manufacturing. These parameter optimizations enable higher therapeutic concentrations while maintaining formulation stability and preventing compound degradation
Solution Approach 2:
Disodium edetate is introduced as a chelating agent that binds metal ions which would otherwise catalyze fosnetupitant degradation. This intermediary substance protects the active ingredient at higher concentrations by eliminating degradation pathways, enabling therapeutic efficacy without compromising stability
3Reliability
If fosnetupitant is administered intravenously to treat chemotherapy induced nausea and vomiting, then therapeutic effectiveness improves, but injection site reactions occur
Solution Approach 1:
The patent optimizes pH to physiological ranges (7.0-9.0) that minimize irritation at the injection site while maintaining therapeutic effectiveness. The controlled pH and use of isotonic excipients like mannitol reduce the harmful effects on injection site tissues, allowing reliable intravenous administration for treating chemotherapy induced nausea and vomiting
4Quantity of substance
If fosnetupitant is stored as a liquid solution to maintain solubility, then bioavailability improves, but degradation increases compared to solid form
Solution Approach 1:
The patent optimizes pH parameters (7.0-9.0 for liquid, 7.5-8.5 for lyophilized) and temperature conditions that simultaneously improve solubility and minimize degradation. These parameter optimizations allow liquid formulations to maintain both good bioavailability and acceptable storage stability, resolving the trade-off between these two critical properties
Solution Approach 2:
Disodium edetate and mannitol serve as protective intermediaries that stabilize fosnetupitant in liquid solution during storage. These excipients prevent degradation while maintaining solubility, enabling the formulation to achieve both improved bioavailability (through maintained solubility) and adequate storage stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide stable, soluble, and physiologically balanced solutions that maintain efficacy and safety, preventing degradation and injection site reactions, suitable for treating diseases mediated by the NK1 receptor.
Implementation Method 1
controlled pH, and specific excipients like sodium hydroxide and disodium edetate to maintain stability and solubility
Implementation Method 2
specific excipients like sodium hydroxide and disodium edetate to maintain stability and solubility
Implementation Method 3
The development of lyophilized and liquid injectable formulations of fosnetupitant
Data Source
AI summary
Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.